RxDoctor Payments Data

Mary Brandon, NP

Acute Care · Beverly Hills, CANPI 1164632287

Payments from drug & device makers

$1,623in general payments, 2019–2025

Across 17 payments — averaging $95.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$335
  • E.r. Squibb & Sons, L.L.C.$277
  • Astellas Pharma US Inc$259
  • Gilead$184
  • Fresenius Kabi USA, LLC$159
  • AstraZeneca$134
  • plus $275 from 4 others

What the payments were for

  • Food & beverage$1,34783%
  • Education$27617%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,623 in reported general payments places this provider in the 80th percentile of 1,153 acute care providers in California.

See all acute care providers in California

Medicare billing

Part B allowed, 2024
$34,898
Medicare patients
207
Services billed
2,016

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CerdelgaEliglustat Tartrate30$1,506,948
CerezymeImiglucerase38$1,158,645
IbrancePalbociclib41$621,254
KisqaliRibociclib Succinate14$184,134
FabrazymeAgalsidase Beta16$175,832
RevlimidLenalidomide12$167,441
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5011$64,538
ProcritEpoetin Alfa30$53,993
XareltoRivaroxaban24$28,414
EliquisApixaban25$25,290
Exemestane115$24,469
Toremifene Citrate12$13,337
Anastrozole339$5,552
Estradiol51$5,272
Letrozole142$4,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
SanofiCerdelga, Cerezyme, Fabrazyme$22$2,841,42584 claims
PfizerIbrance, Eliquis$105$646,54466 claims
Johnson & JohnsonProcrit, Xarelto$335$82,40754 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,153 acute care providers in California.

Other acute care in Beverly Hills

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →